INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

BACKGROUND: Depatuxizumab mafodotin (Depatux-M) is a tumor-specific antibody–drug conjugate consisting of an antibody (ABT-806) directed against activated epidermal growth factor receptor (EGFR) and the toxin monomethylauristatin-F. We investigated Depatux-M in combination with temozolomide or as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Den Bent, Martin, Eoli, Marica, Sepulveda, Juan Manuel, Smits, Marion, Walenkamp, Annemiek, Frenel, Jean-Sebastian, Franceschi, Enrico, Clement, Paul M, Chinot, Olivier, De Vos, Filip, Whenham, Nicolas, Sanghera, Paul, Weller, Michael, Dubbink, H J, French, Pim, Looman, Jim, Dey, Jyotirmoy, Krause, Scott, Ansell, Pete, Nuyens, Sarah, Spruyt, Maarten, Brilhante, Joana, Coens, Corneel, Gorlia, Thierry, Golfinopoulos, Vassilis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229258/
https://www.ncbi.nlm.nih.gov/pubmed/31747009
http://dx.doi.org/10.1093/neuonc/noz222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229258/
https://www.ncbi.nlm.nih.gov/pubmed/31747009
http://dx.doi.org/10.1093/neuonc/noz222

Ejemplares similares